Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Diabetic Neuropathic Pain Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Diabetic Neuropathic Pain Drug Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Diabetic Neuropathic Pain Drug Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type
    • 1.4.2 AZD-5213
    • 1.4.3 Clonidine Hydrochloride
    • 1.4.4 Duloxetine Hydrochloride DR
    • 1.4.5 E-52862
    • 1.4.6 Filgrastim
    • 1.4.7 GERPOOI
    • 1.4.8 GRC-17536
    • 1.4.9 Others
  • 1.5 Market by Application
    • 1.5.1 Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application
    • 1.5.2 Clinic
    • 1.5.3 Hospital
    • 1.5.4 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Diabetic Neuropathic Pain Drug Market Size, Estimates and Forecasts
    • 2.1.1 Global Diabetic Neuropathic Pain Drug Revenue 2015-2026
    • 2.1.2 Global Diabetic Neuropathic Pain Drug Sales 2015-2026
  • 2.2 Global Diabetic Neuropathic Pain Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Diabetic Neuropathic Pain Drug Competitor Landscape by Players

  • 3.1 Diabetic Neuropathic Pain Drug Sales by Manufacturers
    • 3.1.1 Diabetic Neuropathic Pain Drug Sales by Manufacturers (2015-2020)
    • 3.1.2 Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Diabetic Neuropathic Pain Drug Revenue by Manufacturers
    • 3.2.1 Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2015-2020)
    • 3.2.2 Diabetic Neuropathic Pain Drug Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Diabetic Neuropathic Pain Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Diabetic Neuropathic Pain Drug Revenue in 2019
    • 3.2.5 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Diabetic Neuropathic Pain Drug Price by Manufacturers
  • 3.4 Diabetic Neuropathic Pain Drug Manufacturing Base Distribution, Product Types
    • 3.4.1 Diabetic Neuropathic Pain Drug Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Diabetic Neuropathic Pain Drug Product Type
    • 3.4.3 Date of International Manufacturers Enter into Diabetic Neuropathic Pain Drug Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Diabetic Neuropathic Pain Drug Market Size by Type (2015-2020)
    • 4.1.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2015-2020)
    • 4.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2015-2020)
    • 4.1.3 Diabetic Neuropathic Pain Drug Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Diabetic Neuropathic Pain Drug Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Type (2021-2026)
    • 4.2.3 Diabetic Neuropathic Pain Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Diabetic Neuropathic Pain Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Diabetic Neuropathic Pain Drug Market Size by Application (2015-2020)
    • 5.1.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2015-2020)
    • 5.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2015-2020)
    • 5.1.3 Diabetic Neuropathic Pain Drug Price by Application (2015-2020)
  • 5.2 Diabetic Neuropathic Pain Drug Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Diabetic Neuropathic Pain Drug Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Diabetic Neuropathic Pain Drug by Country
    • 6.1.1 North America Diabetic Neuropathic Pain Drug Sales by Country
    • 6.1.2 North America Diabetic Neuropathic Pain Drug Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
  • 6.3 North America Diabetic Neuropathic Pain Drug Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Diabetic Neuropathic Pain Drug by Country
    • 7.1.1 Europe Diabetic Neuropathic Pain Drug Sales by Country
    • 7.1.2 Europe Diabetic Neuropathic Pain Drug Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
  • 7.3 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Diabetic Neuropathic Pain Drug by Region
    • 8.1.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Region
    • 8.1.2 Asia Pacific Diabetic Neuropathic Pain Drug Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
  • 8.3 Asia Pacific Diabetic Neuropathic Pain Drug Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Diabetic Neuropathic Pain Drug by Country
    • 9.1.1 Latin America Diabetic Neuropathic Pain Drug Sales by Country
    • 9.1.2 Latin America Diabetic Neuropathic Pain Drug Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
  • 9.3 Central & South America Diabetic Neuropathic Pain Drug Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Diabetic Neuropathic Pain Drug by Country
    • 10.1.1 Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country
    • 10.1.2 Middle East and Africa Diabetic Neuropathic Pain Drug Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Type
  • 10.3 Middle East and Africa Diabetic Neuropathic Pain Drug Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Astellas Pharma Inc. Corporation Information
    • 11.1.2 Astellas Pharma Inc. Description and Business Overview
    • 11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
    • 11.1.5 Astellas Pharma Inc. Related Developments
  • 11.2 AstraZeneca Plc
    • 11.2.1 AstraZeneca Plc Corporation Information
    • 11.2.2 AstraZeneca Plc Description and Business Overview
    • 11.2.3 AstraZeneca Plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Products Offered
    • 11.2.5 AstraZeneca Plc Related Developments
  • 11.3 BioDelivery Sciences International, Inc.
    • 11.3.1 BioDelivery Sciences International, Inc. Corporation Information
    • 11.3.2 BioDelivery Sciences International, Inc. Description and Business Overview
    • 11.3.3 BioDelivery Sciences International, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Products Offered
    • 11.3.5 BioDelivery Sciences International, Inc. Related Developments
  • 11.4 Boehringer Ingelheim GmbH
    • 11.4.1 Boehringer Ingelheim GmbH Corporation Information
    • 11.4.2 Boehringer Ingelheim GmbH Description and Business Overview
    • 11.4.3 Boehringer Ingelheim GmbH Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Products Offered
    • 11.4.5 Boehringer Ingelheim GmbH Related Developments
  • 11.5 Daiichi Sankyo Company, Limited
    • 11.5.1 Daiichi Sankyo Company, Limited Corporation Information
    • 11.5.2 Daiichi Sankyo Company, Limited Description and Business Overview
    • 11.5.3 Daiichi Sankyo Company, Limited Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Products Offered
    • 11.5.5 Daiichi Sankyo Company, Limited Related Developments
  • 11.6 Dong-A Socio Group
    • 11.6.1 Dong-A Socio Group Corporation Information
    • 11.6.2 Dong-A Socio Group Description and Business Overview
    • 11.6.3 Dong-A Socio Group Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Products Offered
    • 11.6.5 Dong-A Socio Group Related Developments
  • 11.7 Eli Lilly and Company
    • 11.7.1 Eli Lilly and Company Corporation Information
    • 11.7.2 Eli Lilly and Company Description and Business Overview
    • 11.7.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Products Offered
    • 11.7.5 Eli Lilly and Company Related Developments
  • 11.8 Glenmark Pharmaceuticals Ltd.
    • 11.8.1 Glenmark Pharmaceuticals Ltd. Corporation Information
    • 11.8.2 Glenmark Pharmaceuticals Ltd. Description and Business Overview
    • 11.8.3 Glenmark Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Products Offered
    • 11.8.5 Glenmark Pharmaceuticals Ltd. Related Developments
  • 11.9 Hydra Biosciences, Inc.
    • 11.9.1 Hydra Biosciences, Inc. Corporation Information
    • 11.9.2 Hydra Biosciences, Inc. Description and Business Overview
    • 11.9.3 Hydra Biosciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Products Offered
    • 11.9.5 Hydra Biosciences, Inc. Related Developments
  • 11.10 Immune Pharmaceuticals Inc.
    • 11.10.1 Immune Pharmaceuticals Inc. Corporation Information
    • 11.10.2 Immune Pharmaceuticals Inc. Description and Business Overview
    • 11.10.3 Immune Pharmaceuticals Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Products Offered
    • 11.10.5 Immune Pharmaceuticals Inc. Related Developments
  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Astellas Pharma Inc. Corporation Information
    • 11.1.2 Astellas Pharma Inc. Description and Business Overview
    • 11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
    • 11.1.5 Astellas Pharma Inc. Related Developments
  • 11.12 Lohocla Research Corporation
    • 11.12.1 Lohocla Research Corporation Corporation Information
    • 11.12.2 Lohocla Research Corporation Description and Business Overview
    • 11.12.3 Lohocla Research Corporation Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Lohocla Research Corporation Products Offered
    • 11.12.5 Lohocla Research Corporation Related Developments
  • 11.13 Mertiva AB
    • 11.13.1 Mertiva AB Corporation Information
    • 11.13.2 Mertiva AB Description and Business Overview
    • 11.13.3 Mertiva AB Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Mertiva AB Products Offered
    • 11.13.5 Mertiva AB Related Developments
  • 11.14 Novaremed
    • 11.14.1 Novaremed Corporation Information
    • 11.14.2 Novaremed Description and Business Overview
    • 11.14.3 Novaremed Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Novaremed Products Offered
    • 11.14.5 Novaremed Related Developments
  • 11.15 Pharmaleads
    • 11.15.1 Pharmaleads Corporation Information
    • 11.15.2 Pharmaleads Description and Business Overview
    • 11.15.3 Pharmaleads Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Pharmaleads Products Offered
    • 11.15.5 Pharmaleads Related Developments
  • 11.16 RAPID Pharmaceuticals AG
    • 11.16.1 RAPID Pharmaceuticals AG Corporation Information
    • 11.16.2 RAPID Pharmaceuticals AG Description and Business Overview
    • 11.16.3 RAPID Pharmaceuticals AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.16.4 RAPID Pharmaceuticals AG Products Offered
    • 11.16.5 RAPID Pharmaceuticals AG Related Developments
  • 11.17 Relmada Therapeutics, Inc.
    • 11.17.1 Relmada Therapeutics, Inc. Corporation Information
    • 11.17.2 Relmada Therapeutics, Inc. Description and Business Overview
    • 11.17.3 Relmada Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.17.4 Relmada Therapeutics, Inc. Products Offered
    • 11.17.5 Relmada Therapeutics, Inc. Related Developments
  • 11.18 Sphaera Pharma Pvt. Ltd.
    • 11.18.1 Sphaera Pharma Pvt. Ltd. Corporation Information
    • 11.18.2 Sphaera Pharma Pvt. Ltd. Description and Business Overview
    • 11.18.3 Sphaera Pharma Pvt. Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.18.4 Sphaera Pharma Pvt. Ltd. Products Offered
    • 11.18.5 Sphaera Pharma Pvt. Ltd. Related Developments
  • 11.19 Theravasc, Inc.
    • 11.19.1 Theravasc, Inc. Corporation Information
    • 11.19.2 Theravasc, Inc. Description and Business Overview
    • 11.19.3 Theravasc, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.19.4 Theravasc, Inc. Products Offered
    • 11.19.5 Theravasc, Inc. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Diabetic Neuropathic Pain Drug Market Estimates and Projections by Region
    • 12.1.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Regions 2021-2026
  • 12.2 North America Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
    • 12.2.1 North America: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
    • 12.2.2 North America: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
    • 12.2.3 North America: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
    • 12.3.2 Europe: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Diabetic Neuropathic Pain Drug Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Diabetic Neuropathic Pain Drug Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Diabetic Neuropathic Pain Drug Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Diabetic Neuropathic Pain Drug Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Diabetic Neuropathic Pain Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Diabetic Neuropathic Pain Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Diabetic Neuropathic Pain Drug Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Diabetic Neuropathic Pain Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Neuropathic Pain Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Diabetic Neuropathic Pain Drug market is segmented into
    AZD-5213
    Clonidine Hydrochloride
    Duloxetine Hydrochloride DR
    E-52862
    Filgrastim
    GERPOOI
    GRC-17536
    Others

    Segment by Application, the Diabetic Neuropathic Pain Drug market is segmented into
    Clinic
    Hospital
    Others

    Regional and Country-level Analysis
    The Diabetic Neuropathic Pain Drug market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Diabetic Neuropathic Pain Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Diabetic Neuropathic Pain Drug Market Share Analysis
    Diabetic Neuropathic Pain Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Diabetic Neuropathic Pain Drug business, the date to enter into the Diabetic Neuropathic Pain Drug market, Diabetic Neuropathic Pain Drug product introduction, recent developments, etc.

    The major vendors covered:
    Astellas Pharma Inc.
    AstraZeneca Plc
    BioDelivery Sciences International, Inc.
    Boehringer Ingelheim GmbH
    Daiichi Sankyo Company, Limited
    Dong-A Socio Group
    Eli Lilly and Company
    Glenmark Pharmaceuticals Ltd.
    Hydra Biosciences, Inc.
    Immune Pharmaceuticals Inc.
    Laboratorios Del Dr. Esteve S.A.
    Lohocla Research Corporation
    Mertiva AB
    Novaremed
    Pharmaleads
    RAPID Pharmaceuticals AG
    Relmada Therapeutics, Inc.
    Sphaera Pharma Pvt. Ltd.
    Theravasc, Inc.

    Buy now